Global revenues for Imbruvica declined 25% due to pricing pressure and lower demand in the United States. This adds to the company's challenge of offsetting revenue declines from its mature product portfolio.
Filing excerpt
AbbVie's global Imbruvica revenues decreased 25% for the three months ended March 31, 2026 primarily driven by unfavorable pricing and decreased demand in the United States, partially offset by increased collaboration revenues.
What this signalsFilings often name leadership changes, deals and spending plans.
Regions named
sec-10qpricingPressureGet every 10-Q signal for AbbVie and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AbbVie this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/be81c670-a9d1-41d7-ad96-dfca32b98c6d returns this record as JSON. POST /v1/companies/enrich returns every signal for abbvie.com.
{
"signal_id": "be81c670-a9d1-41d7-ad96-dfca32b98c6d",
"signal_type": "sec-10q",
"signal_subtype": "pricingPressure",
"detected_at": "2026-05-12T09:24:57.857+00:00",
"company": {
"name": "AbbVie",
"domain": "abbvie.com"
},
"data": {
"detail": "Global revenues for Imbruvica declined 25% due to pricing pressure and lower demand in the United States. This adds to the company's challenge of offsetting revenue declines from its mature product portfolio.",
"metrics": {
"pct": -25,
"timeframe": "current_quarter",
"pct_context": "YoY decrease in global Imbruvica revenues"
},
"summary": "Imbruvica revenue drops 25% driven by unfavorable pricing and decreased demand",
"excerpts": "AbbVie's global Imbruvica revenues decreased 25% for the three months ended March 31, 2026 primarily driven by unfavorable pricing and decreased demand in the United States, partially offset by increased collaboration revenues.",
"relevance": 0.8,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000017/abbv-20260331.htm",
"filing_date": "2026-05-08",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "03/31",
"sales_relevance": "Cost optimization needed",
"signal_category": "market",
"regions_mentioned": [
"United States"
]
}
}
curl https://signals.autobound.ai/v1/signals/be81c670-a9d1-41d7-ad96-dfca32b98c6d \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbvie.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.